Black Swan Pharmaceuticals
Wake Forest, US · Founded 2018 · Delaware corporation
Founders & leadership
JA
Julian ArbuckleNamed on SEC filing
CM
Craig MetzNamed on SEC filing
AA
Anthony AkkariNamed on SEC filing
SA
Steve ArnottNamed on SEC filing
OD
Om DhingraNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2M disclosed across 2 rounds · 2020–2021
▶$1.9MraisedSep 2021 · 5 investors · PharmaceuticalsRule 506(b)
▶$1.9MraisedSep 2021 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Om DhingraDirector
- Anthony AkkariDirector
- Steve ArnottDirector
- Julian ArbuckleDirector
- Craig MetzExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.9M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$130.2KraisedApr 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$130.2KraisedApr 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Julian ArbuckleDirector
- Craig MetzExecutive Officer, Director
- Anthony AkkariDirector
- Steve ArnottDirector
- Om DhingraDirector
- Offering amount
- $600K
- Amount sold
- $130.2K
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Black Swan Pharmaceuticals raised?
- Black Swan Pharmaceuticals has disclosed $2M raised across 2 rounds.
- Where is Black Swan Pharmaceuticals headquartered?
- Black Swan Pharmaceuticals is headquartered in Wake Forest, US.